Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy

Z. Liu, R. W. Yelverton, B. Kraft, S. B. Tanner, N. J. Olsen, T. M. Aune

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Atopic diseases, resulting from hypersensitivity to a wide variety of allergens, affect 10-20% of the population. Immunotherapy is an effective treatment for atopic diseases, but its mechanisms are not fully understood. Objective: We studied gene expression profiles in the peripheral blood mononuclear cells (PBMC) and examined whether the individuals with allergic rhinitis (AR) have a unique gene expression profile and how the immunotherapy affect the gene expression profiles. Methods: We used cDNA microarray and 'expression analysis systemic explorer' to examine the gene expression profiles in the PBMC of atopic subjects and other groups. Results: We identified a highly conserved gene expression profile in atopic subjects that permitted their accurate segregation from control or autoimmune subjects. A major feature of this profile was the under-expression of a variety of genes that encode proteins required for apoptosis and over-expression of genes that encode proteins critical for stress responses and signal transduction. We also identified 563 genes that can segregate individuals with AR based upon receipt of immunotherapy. Conclusion: There is a highly conserved gene expression profile in the PBMC of individuals with AR. This profile can be used to identify individuals with AR and to evaluate responses to immunotherapy. Quantitative endpoints, such as gene expression, may assist clinicians faced with clinical decisions in the diagnosis of patients and the evaluation of response to therapy. The knowledge of the possible genetic basis for immunotherapy efficacy may also lead to novel therapeutic approaches for atopic diseases.

Original languageEnglish (US)
Pages (from-to)1581-1590
Number of pages10
JournalClinical and Experimental Allergy
Volume35
Issue number12
DOIs
StatePublished - Dec 1 2005

Fingerprint

Transcriptome
Immunotherapy
Blood Cells
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Allergens
Allergic Rhinitis
Signal Transduction
Hypersensitivity
Proteins
Therapeutics
Apoptosis
Gene Expression
Population
Genes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Liu, Z. ; Yelverton, R. W. ; Kraft, B. ; Tanner, S. B. ; Olsen, N. J. ; Aune, T. M. / Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy. In: Clinical and Experimental Allergy. 2005 ; Vol. 35, No. 12. pp. 1581-1590.
@article{b783bce2d27c42f8ae16e1821ad1e029,
title = "Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy",
abstract = "Background: Atopic diseases, resulting from hypersensitivity to a wide variety of allergens, affect 10-20{\%} of the population. Immunotherapy is an effective treatment for atopic diseases, but its mechanisms are not fully understood. Objective: We studied gene expression profiles in the peripheral blood mononuclear cells (PBMC) and examined whether the individuals with allergic rhinitis (AR) have a unique gene expression profile and how the immunotherapy affect the gene expression profiles. Methods: We used cDNA microarray and 'expression analysis systemic explorer' to examine the gene expression profiles in the PBMC of atopic subjects and other groups. Results: We identified a highly conserved gene expression profile in atopic subjects that permitted their accurate segregation from control or autoimmune subjects. A major feature of this profile was the under-expression of a variety of genes that encode proteins required for apoptosis and over-expression of genes that encode proteins critical for stress responses and signal transduction. We also identified 563 genes that can segregate individuals with AR based upon receipt of immunotherapy. Conclusion: There is a highly conserved gene expression profile in the PBMC of individuals with AR. This profile can be used to identify individuals with AR and to evaluate responses to immunotherapy. Quantitative endpoints, such as gene expression, may assist clinicians faced with clinical decisions in the diagnosis of patients and the evaluation of response to therapy. The knowledge of the possible genetic basis for immunotherapy efficacy may also lead to novel therapeutic approaches for atopic diseases.",
author = "Z. Liu and Yelverton, {R. W.} and B. Kraft and Tanner, {S. B.} and Olsen, {N. J.} and Aune, {T. M.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1109/PAC.2005.1590842",
language = "English (US)",
volume = "35",
pages = "1581--1590",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "12",

}

Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy. / Liu, Z.; Yelverton, R. W.; Kraft, B.; Tanner, S. B.; Olsen, N. J.; Aune, T. M.

In: Clinical and Experimental Allergy, Vol. 35, No. 12, 01.12.2005, p. 1581-1590.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy

AU - Liu, Z.

AU - Yelverton, R. W.

AU - Kraft, B.

AU - Tanner, S. B.

AU - Olsen, N. J.

AU - Aune, T. M.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Background: Atopic diseases, resulting from hypersensitivity to a wide variety of allergens, affect 10-20% of the population. Immunotherapy is an effective treatment for atopic diseases, but its mechanisms are not fully understood. Objective: We studied gene expression profiles in the peripheral blood mononuclear cells (PBMC) and examined whether the individuals with allergic rhinitis (AR) have a unique gene expression profile and how the immunotherapy affect the gene expression profiles. Methods: We used cDNA microarray and 'expression analysis systemic explorer' to examine the gene expression profiles in the PBMC of atopic subjects and other groups. Results: We identified a highly conserved gene expression profile in atopic subjects that permitted their accurate segregation from control or autoimmune subjects. A major feature of this profile was the under-expression of a variety of genes that encode proteins required for apoptosis and over-expression of genes that encode proteins critical for stress responses and signal transduction. We also identified 563 genes that can segregate individuals with AR based upon receipt of immunotherapy. Conclusion: There is a highly conserved gene expression profile in the PBMC of individuals with AR. This profile can be used to identify individuals with AR and to evaluate responses to immunotherapy. Quantitative endpoints, such as gene expression, may assist clinicians faced with clinical decisions in the diagnosis of patients and the evaluation of response to therapy. The knowledge of the possible genetic basis for immunotherapy efficacy may also lead to novel therapeutic approaches for atopic diseases.

AB - Background: Atopic diseases, resulting from hypersensitivity to a wide variety of allergens, affect 10-20% of the population. Immunotherapy is an effective treatment for atopic diseases, but its mechanisms are not fully understood. Objective: We studied gene expression profiles in the peripheral blood mononuclear cells (PBMC) and examined whether the individuals with allergic rhinitis (AR) have a unique gene expression profile and how the immunotherapy affect the gene expression profiles. Methods: We used cDNA microarray and 'expression analysis systemic explorer' to examine the gene expression profiles in the PBMC of atopic subjects and other groups. Results: We identified a highly conserved gene expression profile in atopic subjects that permitted their accurate segregation from control or autoimmune subjects. A major feature of this profile was the under-expression of a variety of genes that encode proteins required for apoptosis and over-expression of genes that encode proteins critical for stress responses and signal transduction. We also identified 563 genes that can segregate individuals with AR based upon receipt of immunotherapy. Conclusion: There is a highly conserved gene expression profile in the PBMC of individuals with AR. This profile can be used to identify individuals with AR and to evaluate responses to immunotherapy. Quantitative endpoints, such as gene expression, may assist clinicians faced with clinical decisions in the diagnosis of patients and the evaluation of response to therapy. The knowledge of the possible genetic basis for immunotherapy efficacy may also lead to novel therapeutic approaches for atopic diseases.

UR - http://www.scopus.com/inward/record.url?scp=33646177554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646177554&partnerID=8YFLogxK

U2 - 10.1109/PAC.2005.1590842

DO - 10.1109/PAC.2005.1590842

M3 - Article

C2 - 16393324

AN - SCOPUS:33646177554

VL - 35

SP - 1581

EP - 1590

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 12

ER -